Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Debt to Equity (2019)

Avidity Biosciences (RNA) has disclosed Debt to Equity for 1 consecutive years, with -$0.07 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Debt to Equity changed N/A year-over-year to -$0.07, compared with a TTM value of -$0.07 through Dec 2019, changed N/A, and an annual FY2019 reading of -$0.07, changed N/A over the prior year.
  • Debt to Equity was -$0.07 for Q4 2019 at Avidity Biosciences.
  • Across five years, Debt to Equity topped out at -$0.07 in Q4 2019 and bottomed at -$0.07 in Q4 2019.